Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicofarma BiotechWAR:MDB -1.00%35 Equity-to-Asset is 0.34 as of Jun. 2026, which is 43% below its 10-year median of 0.60. GuruFocus rates WAR:MDB with a GF Score™ of 35/100 and a GF Value™ of zł0.12 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Medicofarma Biotech ranks worse than 80.44% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Medicofarma Biotech's Total Stockholders Equity for the quarter that ended in Jun. 2026 was zł4.51 Mil. Medicofarma Biotech's Total Assets for the quarter that ended in Jun. 2026 was zł13.47 Mil.
Therefore, Medicofarma Biotech's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.34.
The historical rank and industry rank for Medicofarma Biotech's Equity-to-Asset or its related term are showing as below:
WAR:MDB'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.58 Med: 0.6 Max: 0.93
Current: 0.34
During the past 13 years, the highest Equity to Asset Ratio of Medicofarma Biotech was 0.93. The lowest was -0.58. And the median was 0.60.
WAR:MDB's Equity-to-Asset is ranked worse than 80.44% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs WAR:MDB: 0.34
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Medicofarma Biotech Equity-to-Asset Related Terms
Medicofarma Biotech Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Medicofarma Biotech's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:MDB vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medicofarma Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicofarma Biotech Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicofarma Biotech's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Medicofarma Biotech's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Medicofarma Biotech's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicofarma Biotech (WAR:MDB) has a Equity-to-Asset of 0.34 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Medicofarma Biotech and its competitors. This is 43% below median its historical median of 0.60. According to the industry distribution chart, Medicofarma Biotech ranks #810 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 80.4%.
Is Medicofarma Biotech's Equity-to-Asset too high?
Medicofarma Biotech's current Equity-to-Asset of 0.34 is 43% below median its 10-year median of 0.60. The Drug Manufacturers industry median Equity-to-Asset is 0.60. Medicofarma Biotech's value of 0.34 is 43.3% below this industry median. Based on the distribution chart, Medicofarma Biotech ranks #810 out of 1007 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicofarma Biotech has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medicofarma Biotech's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicofarma Biotech ranks #810 out of 1007 companies for Equity-to-Asset. This places Medicofarma Biotech in the lower half of its industry. The industry median Equity-to-Asset is 0.60. Medicofarma Biotech's value of 0.34 is 43.3% below this benchmark. While the company's 10-year median is 0.60 vs. the industry median of 0.60, Medicofarma Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.60, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicofarma Biotech's current Equity-to-Asset of 0.34 is 43.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Medicofarma Biotech and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicofarma Biotech's current Equity-to-Asset is 0.34, which is 43% below median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicofarma Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicofarma Biotech (WAR:MDB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.12, compared to a current price of zł0.40 — trading 231.7% above its estimated fair value. The current Equity-to-Asset is 0.34, which is 43% below median its 10-year median of 0.60 and 43.3% below the Drug Manufacturers industry median of 0.60. Medicofarma Biotech's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Medicofarma Biotech (WAR:MDB), the current Equity-to-Asset is 0.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicofarma Biotech (WAR:MDB) Overvalued in 2026?
Based on GuruFocus' analysis, Medicofarma Biotech stock appears to be overvalued.
The current stock price of zł0.40 is trading 231.7% above its estimated GF Value™ of zł0.12.
GuruFocus considers Medicofarma Biotech to be Significantly Overvalued.
Key valuation signals for WAR:MDB:
Equity-to-Asset: 0.34 (43% below median its 10-year median of 0.60)
GF Value™: zł0.12 vs. price of zł0.40 (231.7% above fair value)
Industry Position: 43.3% below the Drug Manufacturers median (#810 of 1007)
No single metric tells the full story. See the WAR:MDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.
35GF Score
Get the complete analysis for WAR:MDB
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MDB has been successfully added to your 
